Physician profile
Harry Hicklin
NPI 1467959288
$2,466.31
in general payments reported to CMS, 2019-2025
13 companies · $2,083 in 2025
The $2,083 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $383 · 2025: $2,083.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,355 · Travel and Lodging: $1,111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,354.84 |
| Travel and Lodging | $1,111.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,510.89 | 2025 | Optis |
| Boston Scientific Corporation | $507.68 | 2024-2025 | General - Vascular Intervention |
| Stryker Corporation | $139.75 | 2025 | Flowtriever |
| Abiomed | $90.43 | 2025 | |
| Bridgebio Pharma, INC. | $35.73 | 2025 | Attruby |
| Teleflex LLC | $34.19 | 2025 | Turnpike |
| Novartis Pharmaceuticals Corporation | $31.86 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $29.24 | 2025 | |
| Edwards Lifesciences Corporation | $21.09 | 2025 | |
| Amgen INC. | $18.51 | 2025 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $16.93 | 2025 | Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.96 | 2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $14.05 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Harry Hicklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.